Misplaced Pages

Escitalopram: Difference between revisions

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editNext edit →
Revision as of 15:40, 27 October 2005 editJfdwolff (talk | contribs)Administrators81,547 edits drugbox should contain that data, also moving to escitalopram← Previous edit Revision as of 15:41, 27 October 2005 edit undoJfdwolff (talk | contribs)Administrators81,547 editsm Escitalopram oxalate moved to EscitalopramNext edit →
(No difference)

Revision as of 15:41, 27 October 2005

escitalopram (free base) structure
escitalopram (free base) structure

escitalopram (free base)

S-(+)-1--1-(p-fluorophenyl)-5-phthalancarbonitrile oxalate
CAS number
128196-01-0, 219861-08-2 (as oxalate)
ATC code
N06AB10
Chemical formula C20H22FN2O+ C2HO4-
Molecular weight 324.397 or 414.40 (oxalate)
Bioavailability ?
Metabolism ?
Elimination half-life ?
Excretion ?
Pregnancy category C
Legal status ?
Routes of administration ?

Escitalopram (also known as Lexapro and Cipralex) is a medication developed by the Danish pharmaceutical company Lundbeck, that acts as a selective serotonin reuptake inhibitor or SSRI. It is typically used as an antidepressant to treat depression associated with mood disorders although also may be used in the treatment of body dysmorphic disorder and anxiety.

Escitalopram oxalate is derived from the drug citalopram which is made up of two mirror-image isomers, only one of which is thought to be an effective medication. Lundbeck has split the isomers apart, taken the active isomer and has licensed it as the new drug escitalopram. Escitalopram is the pure S-enantiomer (single isomer) of the racemic bicyclic phthalane derivative citalopram.

It is notable that escitalopram was released shortly before the patent for citalopram was due to expire. The expiration of a patent means other companies can legally produce cheaper generic versions. Escitalopram is subject to a new patent. Critics have argued that escitalopram, and the subsequent marketing campaign to persuade mental health professionals to prescribe it, is a cynical ploy to promote sales of a virtually identical but considerably more expensive drug. In defence of the new drug, Lundbeck have claimed that the drug has additional benefits over the older citalopram and other antidepressant drugs on the market.

In the United States, the drug is marketed under the name Lexapro by Forest Laboratories, Inc.

In Canada, the drug is marketed under the name Cipralex by Lundbeck Canada, Inc.

Externals links

Antidepressants (N06A)
Specific reuptake inhibitors and/or receptor modulators
SSRIsTooltip Selective serotonin reuptake inhibitors
SNRIsTooltip Serotonin–norepinephrine reuptake inhibitors
NRIsTooltip Norepinephrine reuptake inhibitors
NDRIsTooltip Norepinephrine–dopamine reuptake inhibitors
NaSSAsTooltip Noradrenergic and specific serotonergic antidepressants
SARIsTooltip Serotonin antagonist and reuptake inhibitors
SMSTooltip Serotonin modulator and stimulators
Others
Tricyclic and tetracyclic antidepressants
TCAsTooltip Tricyclic antidepressants
TeCAsTooltip Tetracyclic antidepressants
Others
Monoamine oxidase inhibitors
Non-selective
MAOATooltip Monoamine oxidase A-selective
MAOBTooltip Monoamine oxidase B-selective
Adjunctive therapies
Miscellaneous
Categories: